Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
IPO Year: 2016
Exchange: NYSE
Website: myovant.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/26/2022 | Outperform → In-line | Evercore ISI | |
| 8/9/2022 | $12.00 → $23.00 | Mkt Perform → Outperform | SVB Leerink |
| 2/16/2022 | $21.00 → $19.00 | Market Perform | SVB Leerink |
| 1/5/2022 | $23.00 → $21.00 | Market Perform | SVB Leerink |
| 10/27/2021 | $24.00 → $23.00 | Market Perform | SVB Leerink |
| 9/9/2021 | $24.00 | Market Perform | SVB Leerink |
| 8/20/2021 | $18.00 | Neutral | Goldman |
15-12G - Myovant Sciences Ltd. (0001679082) (Filer)
EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)
EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)
25-NSE - Myovant Sciences Ltd. (0001679082) (Subject)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
S-8 POS - Myovant Sciences Ltd. (0001679082) (Filer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
4 - Myovant Sciences Ltd. (0001679082) (Issuer)
SC 13D/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13D/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13D/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)
SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. "We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom," said Terrie Curran, President and Chief Executive Officer of Phathom. "Frank's financial, business
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO). Concurrent with this appointment, Dr. Kurstjens will step down as a member of Urovant's Board of Directors, a position he has held since July 2018, to pursue the full-time CMO role. "I am delighted to welcome Sef Kurstjens to the executive leadership team to lead our clinical and medical affairs activities. His appointment reflects his deep commitment to Urovant and improving the lives of people with urological conditions," said James Robinson, president and CEO of Urovant Sciences. "Dr. Kurstjens'
CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams across several geographic markets around the world. She has delivered strong business results for companies such as Novartis, Merck, Mallinckrodt, and Biogen, with a robust track record of bringing new products to market and creating integrated pre-and post-launch commercial plans including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare disease
BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente, M.D. as an independent member of the company's Board of Directors. Dr. Valente is a renowned expert in hematology and oncology drug development with over 20 years of experience leading global development programs at Genentech/Roche and other leading pharmaceutical companies involving novel first-in-class molecules. In addition to her Board appointment, Dr. Valente will chair the Board's Nominating and Corporate Governance Committee and be a member of the Audit C
Laura Genatossio Appointed Senior Vice President and General Manager, Europe Alana Darden Powell Promoted to Vice President, Corporate Communications Mark Niemaszek Named Senior Vice President, Corporate Planning Ted Chan Promoted to Senior Vice President, Associate General Counsel and Head of Intellectual Property Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the appointment of Laura Pala Genatossio as senior vice president and general manager, Europe. The company also announced the promotion of Alana Darden Powell as vice president, corporate communications, and Mark Niemaszek as senior vice president, corporate planning. Genat
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc. Mr. Mehra will succeed Frank Karbe, who has decided to pursue other opportunities and will serve in an advisory capacity to support Mr. Mehra's transition. Beginning September 7, 2021, Mr. Mehra will lead Myovant's finance, alliance partnerships, and business development functions and will be a member of Myovant's Executive Committee, reporting to Dave Marek, Myovant's Chief Executive Officer. Mr. Mehra brings extensive financ
LONDON and NEW YORK, May 26, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant Sciences (NYSE:MYOV), a publicly listed company that is majority owned by Sumitovant, achieved significant clinical and corporate milestones in the company's fourth quarter ending on March 31, 2021. Sumitovant Biopharma Has a Strong Fourth Quarter Across its Portfolio of Companies"We were delighted to see tremendous strides across the Sumitovant portfolio of companies
Fourth fiscal quarter 2020 total revenues of $24.6 million; net product revenue from sales of ORGOVYX in the U.S. of $3.6 millionFDA review of New Drug Application for relugolix combination tablet for uterine fibroids remains on track for a decision by June 1, 2021 target action date; U.S. launch expected in June 2021, if approvedRemain on track to submit U.S. regulatory filing for endometriosis in the second quarter of calendar year 2021European Commission decision on uterine fibroids Marketing Authorization Application remains on track for mid-calendar year 2021; Gedeon Richter to launch and commercialize, if approvedEuropean Medicines Agency validated Marketing Authorization Application f
Evercore ISI downgraded Myovant Sciences from Outperform to In-line
SVB Leerink upgraded Myovant Sciences from Mkt Perform to Outperform and set a new price target of $23.00 from $12.00 previously
SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $19.00 from $21.00 previously
SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $21.00 from $23.00 previously
SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $23.00 from $24.00 previously
SVB Leerink initiated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $24.00
Goldman resumed coverage of Myovant Sciences with a rating of Neutral and set a new price target of $18.00
SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $26.00 from $28.00 previously
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estimated at 13,500 through December 2022Myovant remains well-capitalized with cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement of $315.7 million
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant's 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE's Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 149,300 common shares of Myovant. One-fourth of the shares underlying each employee'
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine
Urovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB) For Patients With OAB, Traveling or Enjoying a Night Out Can Be a Daunting Thought, Worrying Whether They Will Make it in Time to the Bathroom The Newly Launched Time to GoTM Campaign Offers Travel Kits and Helps People Learn About Treatment Options for Managing OAB While Traveling Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational campaign in partnership with Thinx Inc., the leading period and incontinence underwear brand. This campaign highlights t
A new peer-reviewed journal paper suggests that crushing GEMTESA (vibegron) 75-mg and taking it with applesauce may be an appropriate option for people with overactive bladder (OAB) and concommitant swallowing difficulties. Results from this Phase 1 study show that vibegron can be crushed and mixed with applesauce with no clinically meaningful change to pharmacokinetic (PK) parameters or stability. GEMTESA was stable over 4 hours after crushing and mixing in applesauce. In the study, 30 participants were randomized, and 29 were included in the pharmacokinetic (PK) analysis. Patients were randomly assigned to one of two sequences for vibegron formulation administration, ensuring all pat
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion on a fully diluted basisSecond fiscal quarter 2022 total revenue of $104.8 million; including net product revenue of $49.9 millionNet product revenue from U.S. sales of ORGOVYX® of $43.3 million in s
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) ("Myovant") today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and women's health
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant's Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE:MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstandin
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant's Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE:MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant's 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE's Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 96,500 common shares of Myovant. One-fourth of the shares underlying each emp
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) ("Myovant") today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and women's health
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022. Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company's investor relations page of Myovant's website at: https://investors.myovant.com/. The webcast will be archived on the company website for approximately one year. ABOUT MYOVANT SCIENCES Myova
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix
First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 54%MYFEMBREE remains the number one prescribed FDA-approved gonadotropin-releasing hormone (GnRH) antagonist therapy for the treatment of uterine fibroids for new patients and is now the market leader in total prescriptions (TRx) with 51
BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022. Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company's investor relations page of Myovant's website at: https://investors.myovant.com/. The webcast will be archived on the company website for approximately one year. ABOUT MYOVANT SCIENCES Myovant
Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 millionEuropean Commission approval of ORGOVYX® as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe in April 2022Announced exclusive license agreement with Accord Healthcare, Ltd. (Accord) to commercialize ORGOVYX in Europe; total deal value up to $140.5 million, inclusive of upfront payment of $50.0 million, plus tiered royaltiesNet product revenue from U.S. sales of ORGOVYX of $83.0 million in fiscal year 2021; fourth fiscal quarter 20
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2021, ended March 31, 2022. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 10, 2022. Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant's website at https://investors.myovant.com/. Institutional investors and analysts may also participate in the conference call by dialing 1-800-891-3840 in the U.S. or +1-785-424-1677 from outsi
Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 millionNet product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential volume growth compared to second fiscal quarter 2021, partially offset by a lower net priceNet product revenue from U.S. sales of MYFEMBREE® of $2.4 million; New-to-brand prescription (NBRx) share among GnRH antagonist therapies FDA-approved for the treatment of uterine fibroids grew to 45% in December 2021, six months following launchEstimated 11,000 cumulative patients treated with ORGOVYX through December 2021; Approximately 1,800 treatment centers have prescribed ORGOVYX since launchEstimated 1
BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021, ended December 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on January 26, 2022. Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant's website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-8
Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6 millionEstimated 8,000 cumulative patients treated with ORGOVYX through September 2021, including patients on commercial and free drug; Approximately 600 cumulative patients treated with MYFEMBREE through September 2021 including patients on commercial drug and free drug programs, excluding patients utilizing product samplesMYFEMBREE supplemental New Drug Application for the management of moderate to severe pain associated with endometriosis accepted for review by FDA in September 2021; FDA target action date is May 6, 2022RYEQO® approved in the